Miriam Martinez Callejas

Miriam Martinez Callejas is a qualified pharmacist and the Superintendent Pharmacist and co-founder of Roseway Labs, a private compounding pharmacy based in London. Originally from Spain, she completed her Master's Degree in Pharmacy at the University of Alcalá, where she trained in the formulation of medication. During her pre-registration training, she worked in a compounding pharmacy in Spain, where the model differs significantly from that in the UK, with compounding pharmacies routinely supplying hospitals and other pharmacies as well as individual patients. It was through this early experience that she developed both her expertise in personalised medicine and her interest in bioidentical hormones, dermatology, longevity and nutritional supplementation.

Before co-founding Roseway Labs in 2018, Miriam gained clinical pharmacy experience in London, including roles at London Specialist Pharmacy and Seymour Pharmacie. Over her 20-year career in pharmacy and compounding, she has developed a deep practical knowledge of pharmaceutical-grade formulation, product development, and quality assurance in a compounding environment. At Roseway Labs, she oversees all clinical pharmacy operations, new formulation development, training and education for prescribing practitioners, and quality assurance of compounding processes. The pharmacy operates within a regulated framework under GPhC oversight and serves a broad range of private prescribers, including doctors, nurses, dentists, and pharmacists.

Miriam is an active conference speaker and educator across the UK aesthetics, integrative medicine, and women's health sectors. She has spoken at Menopause in Aesthetics (MiA), Aesthetics Medicine Live, the Integrative and Personalised Medicine Congress, the LDN Trust Conference, the Longevity Med Summit, and the British Association of Hormone Replacement Specialists (BAHRS), among others. She trains healthcare practitioners in the prescribing of compounded medications and has been cited in national press and trade publications, including The PMFA Journal, Personal Care Insights, and Roseway Labs' own research publications. She was also featured in the International Women's Day coverage for Roseway Labs, reflecting her prominence as one of the founding clinical voices in the UK's personalised medicine sector.

Roseway Labs, under Miriam's clinical leadership, was awarded Pharma Company of the Year 2024 (SME) at the Pharma Industry Awards UK, and has been shortlisted for the Made in America (MiA) Awards 2025 as a finalist. Miriam's approach is grounded in collaboration with prescribers and patients alike: she believes that compounded medication offers a clinically meaningful and often cost-effective alternative to commercially produced treatments, particularly for patients who have not responded to standard therapies. She brings to every consultation and formulation a principle of personalised care — that treatment should be shaped precisely around the individual rather than adapted to a mass-produced standard.

• MPharm (Master's Degree in Pharmacy) - University of Alcalá, Spain
• Master in Preparation and Development of Individualised Medicines in Pharmacy - TECH Technological University, 2022–2023

• Pharma Company of the Year (SME), Pharma Industry Awards UK, 2024 - Won
• Healthcare Business of the Year (Small), Growing Business Awards, 2024 - Finalist
• MiA Awards, 2025 - Finalist
• Speaker, Longevity Med Summit, London, 2025
• Speaker, Integrative and Personalised Medicine Congress (IPM), 2025 and 2026
• Speaker, Menopause in Aesthetics (MiA), 2024
• Featured Interview, The PMFA Journal (Plastic, Maxillofacial and Facial Aesthetic Journal), July 2025